Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes (Q33909119)

29 July 2017

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes (English)

1 reference

29 July 2017

Michael K Wong

1

1 reference

29 July 2017

Howard L Kaufman

2

1 reference

29 July 2017

Gregory A Daniels

3

1 reference

29 July 2017

David F McDermott

4

1 reference

29 July 2017

Sandra Aung

5

1 reference

29 July 2017

James N Lowder

6

1 reference

29 July 2017

Michael A Morse

7

1 reference

29 July 2017

18 June 2014

1 reference

Journal for Immunotherapy of Cancer

29 July 2017

1 reference

29 July 2017

2

1 reference

29 July 2017

20

1 reference

https://scigraph.springernature.com/pub.10.1186/2051-1426-2-20

29 July 2017

0 references

cites work

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100489

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100489

Does matched unrelated donor transplantation have the same outcome as matched sibling transplantation in unselected patients?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100489

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100489

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100489

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100489

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100489

Guidelines for the safe administration of high-dose interleukin-2.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100489

A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100489

Nivolumab: promising survival signal coupled with limited toxicity raises expectations

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25031835

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/2051-1426-2-20

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference